May 20, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Nebulized LABA plus LAMA product improves FEV 1 , well tolerated in COPD
ORLANDO — Patients with COPD had larger improvements in FEV1 with a nebulized fixed-dose combination of indacaterol and glycopyrrolate vs. placebo, according to results presented at the American Thoracic Society International Conference.The long-acting beta-agonist indacaterol and the long-acting muscarinic antagonist glycopyrrolate make up AERO-007 (AeroRx Therapeutics), according to the
1,116 words~5 min read
